Skip to main content

Drug Interactions between irinotecan and oxaliplatin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

irinotecan oxaliplatin

Applies to: irinotecan and oxaliplatin

MONITOR: Several case reports have suggested that coadministration of oxaliplatin may increase the incidence and/or severity of irinotecan-induced cholinergic syndrome. The mechanism is unknown.

MANAGEMENT: Patients should be monitored for cholinergic symptoms (e.g., rhinitis, miosis, lacrimation, hypersalivation, diaphoresis, flushing, abdominal cramps, and diarrhea). Subcutaneous atropine has been used to prevent and treat symptoms.

References (3)
  1. Dodds HM, Bishop JF, Rivory LP (1999) "More about: irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin." J Natl Cancer Inst, 91, p. 91-2
  2. Cvitkovic E, Marty M, Wasserman E, Cuvier C, Goldwasser F, Misset JL (1998) "Re: Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin." J Natl Cancer Inst, 90, p. 1016-7
  3. Valencak J, Raderer M, Kornek GV, Henja MH, Scheithauer W (1998) "Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin." J Natl Cancer Inst, 90, p. 160

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer